key: cord-0703025-9uglcnyb authors: Yin Wong, Lydia Su; Ling Loo, Evelyn Xiu; Hui Kang, Alicia Yi; Lau, Hui Xing; Tambyah, Paul Anantharajah; Tham, Elizabeth Huiwen title: Age-Related differences in immunological responses to SARS-CoV-2 date: 2020-08-27 journal: J Allergy Clin Immunol Pract DOI: 10.1016/j.jaip.2020.08.026 sha: ba0a2162fa7a244f2227ff466ba74d485fd04acb doc_id: 703025 cord_uid: 9uglcnyb There is a striking age-related disparity in the prevalence and severity of SARS-CoV-2 induced COVID-19 infections, which might be explained by age-dependent immunological mechanisms. These include age-related physiological differences in immunological responses, cross-neutralizing antibodies, differences in levels and binding affinity of ACE-2, the SARS-CoV-2 target receptor; antibody dependent enhancement (ADE) in adults manifesting with an over-exuberant systemic inflammation in response to infection; and the increased likelihood of co-morbidities in adults and the elderly. Emerging immunological phenomena such as PMIS-TS (Paediatric Multi-System Inflammatory Disorder Temporally associated with SARS-CoV-2) or MIS-C (Multisystem Inflammatory Syndrome in Children are now being observed, though the underlying mechanisms are still unclear. Understanding the mechanisms through which pediatric patients are protected from severe novel coronaviruses infections will provide critical clues to the pathophysiology of COVID-19 infection and inform future therapeutic and prophylactic interventions. Asymptomatic carriage in children may have major public health implications which impact on social and healthcare policies on screening and isolation practices, school reopening and safe distancing requirements in the community. HCoV-OC43 increased rapidly up to age 14 before tapering off and decreasing after 157 age 60. 13 As this protective cross-neutralizing effect may be attenuated with the 158 waning of neutralizing antibody titres with age, this may possibly manifest as higher 159 infection rates and more severe disease presentation in adulthood. Unique epidemiological and clinical features of the 456 emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures Systematic review of COVID-19 in children shows milder cases and a better 459 prognosis than adults Epidemiological characteristics of 2143 461 pediatric patients with 2019 coronavirus disease in China SARS-CoV-2 Infection in Children Case-Fatality Rate and Characteristics of Patients Dying in 468 Relation to COVID-19 in Italy The 470 dominance of human coronavirus OC43 and NL63 infections in infants Journal of clinical virology : the official publication of the Pan American Society for 474 Clinical Virology Examination of seroprevalence of 476 coronavirus HKU1 infection with S protein-based ELISA and neutralization assay against viral spike 477 pseudotyped virus Human 480 coronavirus NL63 and 229E seroconversion in children Journal of clinical virology : 484 the official publication of the Pan American Society for Clinical Virology OC43 strain-related coronavirus antibodies in 486 different age groups The potential danger of suboptimal antibody responses in COVID-19. 488 Laboratory abnormalities in children with novel coronavirus 540 disease 2019 Plasma inflammatory cytokines and 542 chemokines in severe acute respiratory syndrome Targeting coronaviral 545 replication and cellular JAK2 mediated dominant NF-κB activation for comprehensive and ultimate 546 inhibition of coronaviral activity Severe acute respiratory syndrome (SARS) 548 coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic 549 functions of monocyte-derived macrophages and dendritic cells Systems-level 552 immunomonitoring from acute to recovery phase of severe Chronic inflammation (inflammaging) and its potential contribution 555 to age-associated diseases. The journals of gerontology Series A, Biological sciences and medical 556 sciences An evolutionary perspective on immunosenescence Aging and the Immune System: the Impact of Immunosenescence on 560 Viral Infection, Immunity and Vaccine Immunogenicity Age-associated 565 decrease in TLR function in primary human dendritic cells predicts influenza vaccine response Why does COVID-19 disproportionately affect older 570 people? Aging Aging of the innate immune system. 572 Current opinion in immunology Inflammaging and the Lung Single-cell landscape of bronchoalveolar 576 immune cells in patients with COVID-19 Angiotensin-converting enzyme 2 (ACE2) in 578 disease pathogenesis Good ACE, bad ACE do battle in lung injury, SARS. Nature medicine Role of the renin-angiotensin 582 system in ventilator-induced lung injury: an in vivo study in a rat model ACE2/Angiotensin 1-7 protective antiinflammatory and 584 antioxidant role in hyperoxic lung injury: support from studies in Bartter's and Gitelman's 585 syndromes Angiotensin-converting enzyme 2 587 protects from severe acute lung failure Angiotensin-converting enzyme 2 attenuates inflammatory response 589 and oxidative stress in hyperoxic lung injury by regulating NF-κB and Nrf2 pathways. QJM: An 590 COVID-19 -Does This Disease Kill Due to Imbalance of the System (RAS) Caused by Genetic and Gender Differences in the Response to Viral ACE 2 Attack? 593 Heart Lung Circ The Dilemma of Coronavirus Disease 2019, Aging, and 595 Cardiovascular Disease: Insights From Cardiovascular Aging Science. JAMA Cardiology. 2020. 596 58. Bunyavanich S, Do A, Vicencio A. Nasal Gene Expression of Angiotensin-Converting Enzyme 2 597 in Children and Adults Expression of the SARS-CoV-2 Entry 599 Cells of the Olfactory Epithelium: Identification of Cell Types and 600 Trends with Age Prevalence and impact of cardiovascular 602 metabolic diseases on COVID-19 in China. Clinical research in cardiology : official journal of the 603 German Cardiac Society Coronavirus Disease 605 2019 (COVID-19) and Cardiovascular Disease SARS-coronavirus 607 modulation of myocardial ACE2 expression and inflammation in patients with SARS. European 608 journal of clinical investigation Expression of elevated levels of pro-613 inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung 614 injury and pathogenesis of SARS Are patients with hypertension and diabetes mellitus at 616 increased risk for COVID-19 infection? The Lancet Respiratory Medicine ACE inhibitors-angiotensin II receptor antagonists: A 618 useful combination therapy for ischemic heart disease. Open access emergency medicine: OAEM Human 621 intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors. Amino 622 acids Unravelling the human genome-phenome relationship 626 using phenome-wide association studies Exploring diseases/traits and blood proteins causally related to 628 expression of ACE2, the putative receptor of 2019-nCov: A Mendelian Randomization analysis. 629 medRxiv The imbalance of Th17/Th1/Tregs in 631 patients with type 2 diabetes: relationship with metabolic factors and complications Diabetes is a risk factor for the 634 progression and prognosis of COVID-19. Diabetes/metabolism research and reviews SARS-CoV-2 invades host cells via a 636 novel route: CD147-spike protein A regulatory loop involving miR-22 Myc modulates CD147 expression in breast cancer invasion and metastasis. Cancer 639 research Effects of matrix metalloproteinase inhibitor 641 doxycycline and CD147 antagonist peptide-9 on gallbladder carcinoma cell lines. Tumor Biology Guidance: Paediatric multisystem inflammatory syndrome temporally associated with 648 COVID-19 Royal College of Paediatrics and Child Health2020 Clinical Characteristics 652 of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With 653 SARS-CoV-2 An outbreak of 655 severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational 656 cohort study. The Lancet Multisystem 658 Inflammatory Syndrome in Children Hospitalizations for Kawasaki syndrome among children in the United States Kawasaki 665 disease: guidelines of the Italian Society of Pediatrics, part I -definition, epidemiology, 666 etiopathogenesis, clinical expression and management of the acute phase Possible involvement of 669 infection with human coronavirus 229E, but not NL63, in Kawasaki disease Lack of association between New Haven 674 coronavirus and Kawasaki disease Effectiveness of convalescent plasma therapy in 676 severe COVID-19 patients Antibody therapies for the prevention and treatment of 679 viral infections Clinical characteristics of 24 asymptomatic 683 infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci Clinical infectious diseases : an official 686 publication of the Infectious Diseases Society of America Disappearance of antibodies to SARS-688 associated coronavirus after recovery. The New England journal of medicine Longitudinal profile of antibodies against SARS-690 coronavirus in SARS patients and their clinical significance Figure 1. Differences in physiological responses of children, adults and elderly 699 to SARS-Cov-2 virus Children generally experience infrequent, mild and self-limiting infections which may 701 be due to a) higher levels of cross-neutralizing antibodies, b) lower levels of ACE-2 702 receptors in nasal epithelium which lowers susceptibility to infection, c) immature B 703 and T cells and higher regulatory T cells responses and d) lower IL-6 and TNF-α 704 production, limiting inflammatory response. Moreover, adults may experience 705 antibody-dependent enhancement where the spike protein enhances entry into cells 706 via Fc receptors, resulting in cytokine storms which cause severe lung injury. Elderly 707 may be even more susceptible to antibody-dependent enhancement as they have 708 more afucosylated IgG which has a higher affinity with Fc receptors. Existing 709 comorbidities in elderly also result in upregulation of CD147